Skip to main content

Table 2 The mean (standard deviation) scores of ABC subscales in the N-Acetylcysteine + risperidone group and Placebo+risperidone group

From: A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders

Subscale

Group

Baseline score

One month after the onset of intervention

Two months after the onset of intervention

Between groups difference

Irritability

N-Acetylcysteine + risperidone

13.2(5.3)

10.0(4.1)

9.7(4.1)

F1,29= 4.9, P<0.035

Placebo+Risperidone

16.7(7.8)

15.5(7.9)

15.1(7.8)

Hyperactivity and Noncompliance

N-Acetylcysteine + risperidone

29.3(6.4)

21.4(7.7)

18.3(6.9)

F1,29= 2.4, P=0.12

Placebo+Risperidone

31.9(8.9)

26.8(11.0)

24.3(12.1)

Lethargy and Social Withdrawal

N-Acetylcysteine + risperidone

11.9(6.5)

9.0(5.7)

8.5(6.5)

F1,28= 0.4, P=0.53

Placebo+Risperidone

12.2(8.3)

11.0(7.8)

10.9(7.5)6

Stereotypic Behavior

N-Acetylcysteine + risperidone

6.6(4.5)

4.5(3.6)

3.9(2.7)

F1,28= 2.8, P=0.1

Placebo+Risperidone

8.5(6.3)

7.7(6.2)

7.8(6.6)

Inappropriate Speech

N-Acetylcysteine + risperidone

3.9(3.7)

3.8(3.7)

3.2(3.4)

F1,29= 1.8, P=0.1

Placebo+Risperidone

5.7(3.8)

5.3(3.7)

5.2(4.0)